ストックスクリーナーアプリを入手
8.47
3.97%
-0.35
プレマーケット:
8.70
0.23
+2.72%
前日終値:
$8.82
開ける：
$8.935
24時間の取引高:
31.49M
Relative Volume:
0.90
時価総額：
$8.71B
収益：
$113.29M
当期純損益:
$-351.47M
株価収益率:
-21.73
EPS:
-0.3898
ネットキャッシュフロー:
$-309.19M
1週間 パフォーマンス:
+0.95%
1か月 パフォーマンス:
-2.64%
6か月 パフォーマンス:
+210.26%
1年 パフォーマンス:
+208.00%
1日の値動き範囲:
$8.40
$9.32
1週間の範囲:
$8.022
$9.32
52週間の値動き範囲:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Compare IBRX vs VRTX, REGN, ALNY, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.47 | 8.71B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
すべてを表示
Immunitybio Inc (IBRX) 最新ニュース
ImmunityBio Inc stock surges on promising Phase 3 cancer vaccine data amid biotech rally - AD HOC NEWS
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway - Yahoo Finance
Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era” - Insider Monkey
Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat
BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth - Insider Monkey
ImmunityBio (NASDAQ:IBRX) Stock Price Down 4%Should You Sell? - MarketBeat
ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX) - MarketBeat
First ANKTIVA approval in Asia gives bladder cancer drug a Macau entry - Stock Titan
ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer - Investing.com
ImmunityBio receives Macau approval for bladder cancer drug By Investing.com - Investing.com India
ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline InclusionWhat's Changed - simplywall.st
ImmunityBio receives Macau approval for bladder cancer drug - Investing.com
ImmunityBio announces approval in Macau SAR, China for Anktiva - marketscreener.com
Immunitybio Announces Approval In Macau SAR, China For Anktiva - TradingView
IBRX Stock Rises Premarket As Founder Flags Early Anktiva Immune Data — Macau Nod Fuels Bull Case - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits
ImmunityBio (NASDAQ:IBRX) Shares Up 3%Should You Buy? - MarketBeat
ImmunityBio gains as NCCN guidelines include new Anktiva indication - MSN
After years of delays, new deadline looms in 2028 for drug manufacturing plant in Dunkirk - Buffalo News
Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress - simplywall.st
ImmunityBio Inc Trade Ideas — SWB:26CA - TradingView
ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3%Here's Why - MarketBeat
ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer - Insider Monkey
ImmunityBio (IBRX) climbs 7.3% as firm nears development of 'world bank of NK cells' - MSN
ImmunityBio Stock Jumps on Big Cancer Breakthrough - TipRanks
5 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference - MarketBeat
Heights Capital Management Inc. Purchases New Position in ImmunityBio, Inc. $IBRX - MarketBeat
IBRX Stock Rises After NCCN Guideline Update Expands ANKTIVA’s UseRetail Expects Sales To Surge - Stocktwits
Is 28.9% Fall In ImmunityBio (IBRX) Stock A Buying Opportunity? - Trefis
ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion - Seeking Alpha
ImmunityBio Stock To $6? - Trefis
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga
NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus - Yahoo Finance
ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include AN - PharmiWeb.com
Will Anktiva Remain a Key Factor in ImmunityBio’s Revenue Expansion in 2026? - Bitget
ImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at D. Boral Capital - MarketBeat
Why Is ImmunityBio (IBRX) Stock Jumping Today? ANKTIVA Gains NCCN Backing - Tokenist
Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026? - Yahoo Finance
NCCN expands bladder cancer guidelines to include ImmunityBio drug - Investing.com
IBRX Stock Is Rising Pre-Market On This Cancer Treatment Expansion - Stocktwits
ImmunityBio gains on NCCN guidelines update (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology have been updated to officially include Anktiva (generic name: N-803) in combination with BCG as a treat - Bitget
Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA - Business Wire
IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins - Stocktwits
IBRX stock jumps on progress in NK cell therapy production - MSN
ImmunityBio (NASDAQ:IBRX) Stock Price Down 2.1%Here's What Happened - MarketBeat
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
大文字化:
|
ボリューム (24 時間):